Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors

Shreya Mehta, Philip R. De Reuver*, Preetjote Gill, Juliana Andrici, Lisa D'Urso, Anubhav Mittal, Nick Pavlakis, Stephen Clarke, Jaswinder S. Samra, Anthony J. Gill

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)
21 Downloads (Pure)


Somatostatin receptors (SSTR) are commonly expressed by neuroendocrine tumors. Expression of SSTR-2a and SSTR-5 may impact symptomatic management; however, the impact on survival is unclear. The aim of this study is to correlate SSTR-2a and SSTR-5 expression in pancreatic neuroendocrine tumors (PNETs) with survival. This study is designed to determine the prognostic significance of somatostatin receptors SSTR-2a and SSTR-5 in PNETs. This retrospective cohort study included cases of resected PNETs between 1992 and 2014. Clinical data, histopathology, expression of SSTR and Ki-67 by immunohistochemistry, and long-term survival were analyzed. A total of 99 cases were included in this study. The mean age was 57.8 years (18-87 years) and median tumor size was 25mm (range 8- 160 mm). SSTR-2a and SSTR-5 expression was scored as negative (n=19, 19.2%; n=75, 75.8%, respectively) and positive (n=80, 80.1%; n=24, 24.2%). The median follow-up was 49 months. SSTR-2a expression was associated with improved overall survival, with cumulative survival rates at 1, 3, and 5 years being 97.5%, 91.5%, and 82.9%, respectively. Univariate analysis demonstrated better survival in SSTR-2a positive patients (log rank P=0.04). SSTR-5 expression was not associated with survival outcomes (log rank P=0.94). Multivariate analysis showed that positive SSTR-2a expression is a stronger prognostic indicator for overall survival [Hazard Ratio (HR): 0.2, 95% Confidence interval (CI): 0.1-0.8] compared to high Ki-67 (HR: 0.8, 95% CI: 0.1-5.7). Expression of SSTR-2a is an independent positive prognostic factor for survival in PNETs.

Original languageEnglish
Article numbere1281
Pages (from-to)1-6
Number of pages6
JournalMedicine (United States)
Issue number40
Publication statusPublished - 9 Oct 2015

Bibliographical note

Copyright the Publisher 2015. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.


Dive into the research topics of 'Somatostatin receptor SSTR-2a expression is a stronger predictor for survival than Ki-67 in pancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this